CR in Elderly AML by Age, Treatment, and Disease Status
| . | Placebo . | G-CSF . | Total . |
|---|---|---|---|
| All patients (n = 211) | 50% (52/105) | 41% (43/106) | 45% (95/211) |
| Age (yr) | |||
| 56-64 | 56% (23/41) | 38% (14/37) | 47% (37/78) |
| 65+ | 45% (29/64) | 42% (29/69) | 44% (58/133) |
| Disease status | |||
| De novo | 53% (43/81) | 50% (40/80) | 52% (83/161) |
| Secondary | 38% (9/24) | 12% (3/26) | 24% (12/50) |
| . | Placebo . | G-CSF . | Total . |
|---|---|---|---|
| All patients (n = 211) | 50% (52/105) | 41% (43/106) | 45% (95/211) |
| Age (yr) | |||
| 56-64 | 56% (23/41) | 38% (14/37) | 47% (37/78) |
| 65+ | 45% (29/64) | 42% (29/69) | 44% (58/133) |
| Disease status | |||
| De novo | 53% (43/81) | 50% (40/80) | 52% (83/161) |
| Secondary | 38% (9/24) | 12% (3/26) | 24% (12/50) |